Biochemical (e.g., ALT, AST, Pro-C3, composite fibrosis scores) and imaging-based markers (e.g., liver stiffness) were widely used as secondary or exploratory endpoints and more frequently demonstrated treatment-related changes than histology. Here, GPT is linked to fibrosis.